Ares-Backed LaserAway Weighs Sale in Deal that Could Exceed $2bn

Why It Matters

A $2 billion valuation highlights the premium investors place on recurring‑revenue medspa models and could set a benchmark for future exits. It also signals strong consumer confidence in elective aesthetic services despite broader economic uncertainty.

Key Takeaways

• LaserAway may sell for over $2 billion, per Reuters
• Company generates roughly $150 million EBITDA on 219 U.S. clinics
• Sale follows surge in private‑equity deals in medspa industry
• Ares holds minority stake since 2021, backing rapid expansion
• No clinic closures in 20‑year history, rare in retail aesthetics

Pulse Analysis

The aesthetic medspa market has become a magnet for private‑equity capital, driven by high‑margin services and repeat‑visit revenue streams. Consumers increasingly view procedures such as laser hair removal, skin rejuvenation, and injectable treatments as routine wellness expenses, insulating the sector from typical discretionary‑spending cycles. This demand elasticity has prompted firms like General Atlantic, Leonard Green, and KKR to pile into the space, creating a competitive M&A environment where valuations regularly exceed traditional retail benchmarks.

LaserAway exemplifies the rapid scaling potential that attracts investors. Founded in 2006, the chain grew from 74 locations in 2021 to 219 clinics in 2024, all while maintaining a spotless closure record—a rarity in both retail and medical aesthetics. With an estimated $150 million EBITDA, the business commands a valuation north of $2 billion, implying a multiple of roughly 13‑14 times earnings. Such a premium reflects not only its geographic footprint but also its diversified service menu, which blends high‑ticket laser procedures with lower‑cost injectables, creating a balanced revenue mix that appeals to both investors and consumers.

If the sale proceeds, it could reshape the competitive landscape by consolidating market share among a few well‑capitalized players. A successful exit would likely spur additional fundraising and acquisition activity, as other PE firms scramble to capture similar upside in a fragmented market. For incumbents, the deal underscores the importance of expanding clinic networks without sacrificing service quality, while for consumers it may translate into broader access to advanced aesthetic technologies and potentially more competitive pricing as scale drives efficiencies.